

EBR Systems Shareholder and Investor Webinar

Sunnyvale, California; 28 January 2022: EBR Systems, Inc. (ASX: “EBR”, “EBR Systems”, or the “Company”), developer of the world’s only wireless cardiac pacing system for heart failure, is pleased to invite shareholders and investors to its first live webinar scheduled on:

Date: Wednesday, 2 February 2022

Time: 11.00am – 12.00pm AEDT

Duration: 1 hour

Register: Please click [here](#) to register for the briefing –

<https://register.gotowebinar.com/register/6328994958760552716>

This webinar is an opportunity to hear from EBR’s President and Chief Executive Officer, John McCutcheon and Chairman, Allan Will, who will provide an overview of the WiSE System and cover the Company’s clinical pipeline and outlook for 2022. They will be available to answer questions following the presentation.

We encourage shareholders and investors to submit questions upon pre-registering or to send their questions to info@ebrsystemsinc.com.

This announcement has been authorised for release by John McCutcheon, President and CEO.

For more information, please contact:

Company

John McCutcheon

President & CEO

P: +1 408 720 1906

E: info@ebrsystemsinc.com

Investors

Joel Seah

Vesparum Capital

P: +61 3 8582 4800

E: EBRSystems@vesparum.com

About EBR Systems (ASX: EBR)

Silicon Valley-based EBR Systems (ASX: EBR) is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through wireless cardiac pacing. The patented proprietary Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for cardiac pacing leads, historically the major source of complications and reliability issues in cardiac rhythm disease management. The initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT). Future products potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications.

EBR Systems’ WiSE® Technology

EBR Systems’ WiSE technology is the world’s only wireless, endocardial (inside the heart) pacing system in clinical use for stimulating the heart’s left ventricle. This has long been a goal of cardiac pacing companies since internal stimulation of the left ventricle is thought to be a potentially superior, more anatomically correct pacing location. WiSE technology enables cardiac pacing of the left ventricle with a novel cardiac implant that is roughly the size of a large grain of rice. The need for a pacing wire on the outside of the heart’s left ventricle – and the attendant problems – are potentially eliminated. WiSE is an investigational device and is not currently available for sale in the US.

Foreign Ownership Restriction

EBR's CHES Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of EBR's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.